---
title: "Maze Therapeutics President, R&D and CMO Harold Bernstein disposes of 9,705 common shares for $254,543"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/298361379.md"
description: "Harold Bernstein, President, R&D & CMO of Maze Therapeutics, sold 9,705 common shares on September 4, 2026, at a weighted-average price of $26.22 per share, totaling $254,543. Post-transaction, his holding stands at zero shares."
datetime: "2026-09-08T20:21:27.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/298361379.md)
  - [en](https://longbridge.com/en/news/298361379.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/298361379.md)
generator: "portal-rs"
---

# Maze Therapeutics President, R&D and CMO Harold Bernstein disposes of 9,705 common shares for $254,543

-   Harold Bernstein, President, R&D & CMO, sold 9,705 shares of Maze Therapeutics common stock on Sept. 4, 2026. \* Sale price was USD 26.22 per share on a weighted-average basis. \* Post-transaction holding reported at 0 shares. Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Maze Therapeutics Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0002050172-26-000036), on September 08, 2026, and is solely responsible for the information contained therein. © Copyright 2026 - Public Technologies (PUBT) Original Document: here

### Related Stocks

- [MAZE.US](https://longbridge.com/en/quote/MAZE.US.md)

## Related News & Research

- [Maze Therapeutics CSBO Atul Dandekar disposes of 7,500 common shares worth $202,920.75](https://longbridge.com/en/news/300722738.md)
- [Maze Therapeutics to present Phase 2 HORIZON data for MZE829 in APOL1-mediated kidney disease at ASN Kidney Week 2026](https://longbridge.com/en/news/301072114.md)
- [Maze Therapeutics President, R&D and CMO Harold Bernstein sells 16,141 common shares worth $425,392.65](https://longbridge.com/en/news/297955166.md)
- [Maze Therapeutics President, R&D and CMO Harold Bernstein disposes of USD 445,522 common shares](https://longbridge.com/en/news/295976091.md)
- [Maze Therapeutics CSBO Atul Dandekar disposes of 7,500 common shares worth $204,859.44](https://longbridge.com/en/news/294551532.md)

---
> **Disclaimer: This article is for reference only and does not constitute any investment advice.**